 Yumanity Therapeutics Inc NASDAQ: YMTX reported results from the Phase 1 single ascending dose study in 40-healthy volunteers, evaluating its lead candidate, YTX-7739, an SCD inhibitor, for the treatment of Parkinsons disease. No safety concerns were identified, and YTX-7739 was found to be well-tolerated, with most adverse events being mild or moderate in severity. 